Major players in the medical device realm are in a heated race to develop the first artificial pancreas to help patients with diabetes manage the chronic condition. Just last year, Medtronic (NYSE:MDT) won FDA approval for its MiniMed 670G hybrid-closed loop system.
But while companies compete for the top spot in developing what could be a fundamental change to diabetes management, Paul Strasma and Dr. Jeffrey Joseph of Capillary Biomedicalare focused on optimizing one particularly important part of the system – insulin infusion.
Get the full story at our sister site, Drug Delivery Business News.
The post Capillary Biomedical takes aim at ‘the Achilles heel of diabetes’ appeared first on MassDevice.